[Alefacept. Successful long-term therapy of a severe psoriasis].
Alefacept, a recombinant protein produced by fusion of human LFA(3 )and IgG(1), was the first biologic specially designed and approved for the treatment of psoriasis. Results of clinical trials reveal both an efficacy comparable to established systemic therapies and a high drug safety. A 62-year old male patient with psoriasis and incomplete response to several standard therapies was treated with alefacept (baseline PASI 23.1). After three courses of 15 mg alefacept i.m. weekly for 12 weeks, each followed by a 12 week post-dosing observation period, the PASI regressed to 2.0. Adverse drug reactions were not observed.
Schmitt
J
J
Klinik und Poliklinik für Dermatologie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden.
Stoller
E
E
Wozel
G
G
D000077944:Alefacept; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D013997:Time Factors; D016896:Treatment Outcome
D011993:Recombinant Fusion Proteins; D000077944:Alefacept